IAG933

DRUG2 trials

Sponsors

Moizumi Sanae, Novartis Pharmaceuticals

Conditions

Mesotheliomapatients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusion

Phase 1

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

Active, not recruitingNCT04857372

Novartis PharmaceuticalsMesothelioma

Start: 2021-10-21End: 2027-01-08Updated: 2026-06-22

Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors

Active, not recruitingJPRN-jRCT2031210340

Moizumi Sanaepatients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusion

Start: 2021-10-25Target: 10Updated: 2026-05-25

Related Papers

Targeting the YAP/TAZ mechanotransducers in solid tumour therapeutics

Journal of Cellular and Molecular Medicine2023-05-2521 citations

The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras–MAPK Signaling in Epithelioid Hemangioendothelioma

Clinical Cancer Research2022-04-2028 citations